Mainz Biomed N.V. MYNZ announced a 1-for-40 reverse stock split, effective Dec. 3. The company specializes in the early detection of cancer.

美因茨生物医药公司（Mainz Biomed N.V.MYNZ）宣布，将于12月3日进行一对一的反向股票分割。该公司专门从事癌症的早期检测。

Last month, Mainz Biomed reported a collaborative agreement with Thermo Fisher Scientific Inc. TMO through its subsidiary Life Technologies Corporation.

上个月，美因茨生物医学公司（Mainz Biomed）通过其子公司生命技术公司（Life Technologies Corporation）报告了与Thermo Fisher Scientific Inc.TMO的合作协议。

The collaboration agreement will enable Mainz Biomed and Thermo Fisher to jointly develop and potentially commercialize Mainz Biomed’s Next Generation colorectal cancer screening product.

该合作协议将使美因茨生物医学公司和Thermo Fisher能够共同开发美因茨生物医学公司的下一代结直肠癌筛查产品，并可能将其商业化。

The collaboration will harness Thermo Fisher’s technologies, instrumentation and information translation systems to enable Mainz Biomed to develop proprietary assays for its mRNA-based next-generation colorectal cancer screening tests.

该合作将利用Thermo Fisher的技术、仪器和信息翻译系统，使美因茨生物医药公司能够为其基于mRNA的下一代结直肠癌筛查测试开发专有检测方法。

Mainz Biomed’s flagship non-invasive test targets the early detection of colorectal cancer and focuses on precancerous lesions, particularly advanced adenomas.

美因茨生物医学公司的旗舰非侵入性测试旨在早期发现结直肠癌，并专注于癌前病变，特别是晚期腺瘤。

The collaboration will leverage combined capabilities to deliver testing solutions being developed at Mainz Biomed’s laboratories in Mainz, Germany.

此次合作将利用综合能力，提供位于德国美因茨的美因茨生物医学实验室正在开发的测试解决方案。

Guido Baechler, CEO of Mainz Biomed, said: “This collaboration with Thermo Fisher will be instrumental to our goal to bring to market a home collection colorectal screening tool with highly effective detection of adenomas.”

美因茨生物医学公司首席执行官GuidoBaechler说：“与Thermo Fisher的合作将有助于我们实现将一种能够高效检测腺瘤的家庭收集结直肠筛查工具推向市场的目标。”

In October, Mainz Biomed reported a 4% increase in revenue and a 32% decrease in operational losses for the first half of 2024. These decreases result from the company’s efforts to reduce costs during the first half of the year.

10月，美因茨生物医药公司报告称，2024年上半年收入增长4%，运营亏损减少32%。这些减少是由于该公司在上半年努力降低成本所致。

The company announced significant improvements to its ColoAlert product, which is available across Europe and in select international markets.

该公司宣布对其ColoAlert产品进行重大改进，该产品可在欧洲和选定的国际市场上销售。

The company says that the new proprietary buffer used in ColoAlert significantly reduces the necessity for additional sample submissions, thereby decreasing how long it takes patients to obtain their results.

该公司表示，ColoAlert中使用的新型专有缓冲液大大减少了提交额外样本的必要性，从而减少了患者获得结果所需的时间。

This enhancement enabled ColoAlert to achieve the industry’s lowest retesting rates, ensuring that screening outcomes are delivered within two to three days of arrival at the laboratory.

这一增强功能使ColoAlert能够实现业界最低的重新测试率，确保在到达实验室的两到三天内提供筛查结果。

Price Action: MYNZ stock is down 13.09% at $6.93 at publication Tuesday.

价格走势：周二公布时，新西兰MYNZ股价下跌13.09%，至6.93美元。

Read Next:

阅读下一页：

BlackRock Makes $12 Billion Power Move – Agrees To Acquire HPS To Bolster Private Credit Offerings

Photo: ShutterstockMarket News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

照片：Benzinga API为您带来的ShutterstockMarket新闻和数据©2024 Benzinga.com。Benzinga不提供投资建议。保留所有权利。